JP2019518756A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518756A5
JP2019518756A5 JP2018564884A JP2018564884A JP2019518756A5 JP 2019518756 A5 JP2019518756 A5 JP 2019518756A5 JP 2018564884 A JP2018564884 A JP 2018564884A JP 2018564884 A JP2018564884 A JP 2018564884A JP 2019518756 A5 JP2019518756 A5 JP 2019518756A5
Authority
JP
Japan
Prior art keywords
crystal
former
sodium benzoate
disorder
benzoate compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018564884A
Other languages
English (en)
Japanese (ja)
Other versions
JP6958922B2 (ja
JP2019518756A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/088045 external-priority patent/WO2017215593A1/en
Publication of JP2019518756A publication Critical patent/JP2019518756A/ja
Publication of JP2019518756A5 publication Critical patent/JP2019518756A5/ja
Application granted granted Critical
Publication of JP6958922B2 publication Critical patent/JP6958922B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018564884A 2016-06-13 2017-06-13 安息香酸ナトリウムの共結晶及びその使用 Active JP6958922B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349578P 2016-06-13 2016-06-13
US62/349,578 2016-06-13
PCT/CN2017/088045 WO2017215593A1 (en) 2016-06-13 2017-06-13 Co-crystals of sodium benzoate and uses thereof

Publications (3)

Publication Number Publication Date
JP2019518756A JP2019518756A (ja) 2019-07-04
JP2019518756A5 true JP2019518756A5 (enExample) 2019-10-17
JP6958922B2 JP6958922B2 (ja) 2021-11-02

Family

ID=60663996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018564884A Active JP6958922B2 (ja) 2016-06-13 2017-06-13 安息香酸ナトリウムの共結晶及びその使用

Country Status (13)

Country Link
US (2) US11008277B2 (enExample)
EP (1) EP3468944B1 (enExample)
JP (1) JP6958922B2 (enExample)
KR (1) KR102403048B1 (enExample)
CN (1) CN109563018A (enExample)
CA (1) CA3027297A1 (enExample)
DK (1) DK3468944T3 (enExample)
ES (1) ES2936094T3 (enExample)
FI (1) FI3468944T3 (enExample)
IL (1) IL263492B (enExample)
MX (1) MX2018015397A (enExample)
TW (1) TWI671287B (enExample)
WO (1) WO2017215593A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2765625C2 (ru) 2016-06-13 2022-02-01 Сайньюрекс Интернэшнл (Тайвань) Корп. Сокристаллы бензоата лития и их применения
US11826326B2 (en) 2017-11-22 2023-11-28 Excelsior Pharmatech Labs Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
AU2020229316A1 (en) 2019-02-25 2021-09-16 Rush University Medical Center Compositions including cinnamic acid and methods of use thereof
CA3180941C (en) 2020-06-01 2024-01-02 Rajaram Samant Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498989A (en) 1969-04-16 1970-03-03 American Home Prod Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
US3870715A (en) 1972-03-09 1975-03-11 Nikolaus R Hansl Substituted amino ethyl meta benzoic acid esters
US4041174A (en) 1974-08-16 1977-08-09 Rom-Amer Pharmaceuticals, Ltd. Method of treating depression
US4731379A (en) * 1983-12-07 1988-03-15 H.S.C. Corporation Flea eradicator
US5204356A (en) 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
GB8819494D0 (en) 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
CA2058455A1 (en) * 1990-12-21 1992-06-22 Mark W. Collison Synergistic effect of lantibiotics in combination with selected agents against gram positive bacteria
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
AU668682B2 (en) * 1991-02-22 1996-05-16 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
FR2700117B1 (fr) 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
DE4340273A1 (de) 1993-11-26 1995-06-01 Karla Dr Lehmann Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
US5441981A (en) * 1994-01-27 1995-08-15 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing a halogenated acetophenone and an organic acid
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
DE19925425A1 (de) * 1999-06-02 2000-12-07 Wessollek Heimo Mittel zur Entkeimung bzw. keimreduzierenden Gestaltung von Reinigungs-, Sanitär- und Toilettenartikeln sowie kosmetischen Artikeln, Körperpflegeartikeln und dergleichen verkeimungsgefährdeten Gegenständen
US6362226B2 (en) 1999-12-08 2002-03-26 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
WO2002014286A1 (en) 2000-08-14 2002-02-21 Teva Pharmaceutical Industries Ltd. Preparation of risperidone
MXPA03006321A (es) 2001-01-16 2003-10-06 Genset Sa Tratamiento de trastornos del sistema nervioso central usando antagonistas de d-aminoacido oxidasa y d-aspartato oxidasa.
US20030185754A1 (en) 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US20070053976A1 (en) 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
GEP20094759B (en) 2002-10-24 2009-08-25 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
CA2798615A1 (en) 2003-01-21 2004-08-05 Aptuit (West Lafayette), Llc Novel cocrystallization of hydrochloric acid salt of an active agent
CA2514092C (en) * 2003-01-21 2013-03-19 S.S.C.I., Inc. Novel cocrystallization of hydrochloric acid salt of an active agent
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
EP1628660A4 (en) 2003-06-02 2010-06-02 Samaritan Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR MODULATING THE CORTISOL SERUM MIRRORS
CN101798291A (zh) 2003-12-29 2010-08-11 塞普拉科公司 苯并[d]异噁唑-3-醇DAAO抑制剂
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
CA2556870C (en) 2004-02-18 2014-01-28 Timothy J. Barberich Dopamine-agonist combination therapy for improving sleep quality
JP2007536228A (ja) 2004-05-06 2007-12-13 サイデックス・インコーポレイテッド セルトラリンおよびスルホアルキルエーテルシクロデキストリンを含有するテイストマスク製剤
US7803786B2 (en) 2004-06-17 2010-09-28 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2505808A1 (en) * 2005-05-02 2006-11-02 Julie Danielle Globus Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans
WO2006129160A2 (en) 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
US20110045065A1 (en) 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
GB0603181D0 (en) 2006-02-17 2006-03-29 Merck Sharp & Dohme Treatment of neurodegenerative and psychiatric diseases
US20080045547A1 (en) * 2006-07-07 2008-02-21 Lippa Arnold S Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
WO2008034087A2 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
US20100204204A1 (en) * 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions
US8071143B2 (en) * 2008-04-02 2011-12-06 Brandeis University Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
US20130338199A1 (en) 2008-07-11 2013-12-19 Uday Saxena Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
CN102215816A (zh) * 2008-09-03 2011-10-12 沃泰克斯药物股份有限公司 共晶和包含所述共晶的药物制剂
JP2010106001A (ja) * 2008-10-31 2010-05-13 Theravalues Corp Ppar活性化剤
MX353752B (es) 2009-01-20 2018-01-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco.
PL3650439T3 (pl) 2010-07-23 2021-06-28 Grünenthal GmbH Sole lub kokryształy 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenolu
CA2831086A1 (en) 2011-03-24 2012-09-27 University Of South Florida Lithium compositions
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
US9120766B2 (en) 2011-10-21 2015-09-01 Amri Ssci, Llc Methods of making cocrystals
CA2908440C (en) * 2012-03-30 2021-04-20 Nuformix Limited Tranilast compositions and cocrystals
ES2910003T3 (es) * 2013-04-19 2022-05-11 Univ South Florida Compuestos y composiciones de cocristal iónico de litio de anión orgánico
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
HUE041877T2 (hu) * 2013-10-17 2019-06-28 Vertex Pharma (S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként
WO2015086843A2 (en) * 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
KR102162073B1 (ko) * 2014-03-24 2020-10-07 가오슝 창 궁 메모리얼 하스피털 치매 또는 경도 인지 장애의 예방 또는 치료용 조성물의 제조에 사용하는 벤조산염의 용도
CN103992320A (zh) 2014-05-26 2014-08-20 南京工业大学 一种混悬结晶制备药物共晶的方法
JP6745728B2 (ja) * 2014-05-27 2020-08-26 アール・ジエイ・レイノルズ・タバコ・カンパニー ニコチン塩、共結晶、及び塩共結晶複合体
US9896429B2 (en) * 2014-05-27 2018-02-20 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
KR20170083146A (ko) * 2014-11-19 2017-07-17 러쉬 유니버시티 메디컬 센터 리소좀 질환들의 치료를 위한 방법들 및 조성물들
RU2582962C1 (ru) 2014-12-23 2016-04-27 Ольга Алексеевна Громова Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты)
RU2765625C2 (ru) * 2016-06-13 2022-02-01 Сайньюрекс Интернэшнл (Тайвань) Корп. Сокристаллы бензоата лития и их применения
MX2018015758A (es) 2016-06-14 2019-05-20 Aemerge Llc Reciclaje de hidrocarburos de gases de carbonizacion calientes.
US10064833B2 (en) * 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US9877942B1 (en) * 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof
US20190076472A1 (en) * 2017-09-14 2019-03-14 CT Development One, LLC Hyperammonemia therapy for children suffering from urea cycle disorders
US10098861B1 (en) * 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof

Similar Documents

Publication Publication Date Title
JP2019518756A5 (enExample)
US9701702B2 (en) Metathesis catalysts and methods thereof
US8546500B2 (en) Complexes for use in metathesis reactions
JP2011517443A5 (enExample)
JP2021517901A (ja) アルコラート塩基の存在下でのニコチン酸エチルとn−ビニルピロリドンとの反応によるラセミ体ニコチンの調製及びその後の工程
RU2010119458A (ru) 1,3,5-тризамещенное производное триазола
JP2014506907A5 (enExample)
JP7621289B2 (ja) ベンゾジアゼピン系化合物及びその製造方法並びに医薬における作用
JP2009525312A5 (enExample)
JP2006151999A5 (enExample)
JP2019523279A5 (enExample)
JP2019518757A5 (enExample)
CN104961733A (zh) 雷迪帕韦新晶型及其制备方法
JP6218077B2 (ja) 有機ホウ素化合物及びその製造方法
RU2019128576A (ru) Сокристаллы замещенных глициновых соединений и их применение
JP2019529553A5 (enExample)
JP2020507567A5 (enExample)
RU2018146423A (ru) Сокристаллы бензоата лития и их применения
CN105820184A (zh) 一种4-苯氧基苯硼酸的制备方法
CA2979121A1 (en) Stereoselective synthesis of enantiomers of 8-hydroxyquinoline derivati ves
CN105199017A (zh) 一种Cs-CD-MOFs化合物及其制备方法
RU2019100436A (ru) Сокристаллы бензоата натрия и их применения
JP2011527340A5 (enExample)
El-Kadri et al. Synthesis, structure, properties, volatility, and thermal stability of molybdenum (II) and tungsten (II) complexes containing allyl, carbonyl, and pyrazolate or amidinate ligands
US11020730B2 (en) Halogen-containing metathesis catalysts and methods thereof